Objective Effective screening for pre-eclampsia resulting in delivery < 37 weeks ' gestation (preterm PE) 
INTRODUCTION
In screening for pre-eclampsia (PE), we advocate use of Bayes' theorem to combine the a-priori risk from maternal demographic characteristics and medical history (maternal factors) with the results of various combinations of biophysical and biochemical measurements 1 -4 . This approach of screening, which allows estimation of individual patient-specific risks of PE requiring delivery before any specified gestational age, has a performance which is by far superior to that of risk-scoring systems based on maternal factors alone 3 -6 . We reported recently that screening for PE at 11-13 or 19-24 weeks' gestation by a combination of maternal factors and mean arterial pressure (MAP) can predict about 60% of preterm PE, requiring delivery < 37 weeks, but only about 45% of PE delivering ≥ 37 weeks, at a falsepositive rate (FPR) of 10% 3, 4 . Addition of uterine artery pulsatility index (UtA-PI) and serum placental growth factor (PlGF) improved the detection rate (DR) of preterm PE to about 75% at 11-13 weeks and 85% at 19-24 weeks 3, 4 . Recording of maternal history and measurement of blood pressure are universally carried out as part of routine pregnancy care. In contrast, measurement of UtA-PI requires specific training by sonographers and quality assurance of their results; nevertheless this test can be undertaken within a few minutes by the same sonographers and machines as part of the routine secondtrimester scan. Measurement of serum PlGF can be undertaken on the same machines as for free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A, which are widely used in screening for Down syndrome, but there is an inevitable increase in cost.
The objective of this study was to explore the possibility of carrying out routine screening by maternal factors and MAP in all pregnancies and reserving measurements of UtA-PI and PlGF for only a subgroup of the population, selected on the basis of the risk derived from screening by maternal factors and MAP.
METHODS

Study population
The data for this study were derived from prospective screening for adverse obstetric outcomes in women attending their routine first-and/or second-trimester hospital visits at King's College Hospital, University College London Hospital and Medway Maritime Hospital, UK. These visits, which were held at 11 + 0 to 13 + 6 and 19 + 0 to 24 + 6 weeks' gestation, included first, recording of maternal characteristics and medical history, second, measurement of the left and right UtA-PI by color Doppler ultrasound and calculation of the mean PI by transabdominal ultrasound in the first trimester and by transvaginal ultrasound in the second trimester 7, 8 , third, measurement of MAP by validated automated devices and standardized protocol 9 and fourth, measurement of serum concentration of PlGF by an automated biochemical analyzer within 10 min of blood sampling (Cobas e411 system, Roche Diagnostics, Penzberg, Germany).
Gestational age was determined from measurement of fetal crown-rump length at 11-13 weeks or the fetal head circumference at 19-24 weeks 10, 11 . The women were screened between March 2006 and July 2014 and gave written informed consent to participate in the study, which was approved by the NHS Research Ethics Committee.
The inclusion criteria for this study were singleton pregnancy delivering a morphologically normal live birth or stillbirth at or after 24 weeks' gestation. Pregnancies with aneuploidy or major fetal abnormality and those ending in termination, miscarriage or fetal death < 24 weeks were excluded.
Data on pregnancy outcome were collected from the hospital maternity records or the general medical practitioners of the women. The obstetric records of all women with pre-existing or pregnancy-associated hypertension were examined to determine if the condition was PE, as defined by the International Society for the Study of Hypertension in Pregnancy 12 . The outcome measure for this study was preterm PE.
Statistical analysis
Our competing-risks model for gestational age at delivery with PE is defined by two components: first, the prior distribution based on maternal factors 1 and second, the conditional distribution of multiples of the 4 . Model-based estimates of screening performance were obtained as follows. Samples of 500 000 records with preterm PE and 500 000 without PE or pregnancyinduced hypertension were sampled with replacement from a population of 123 406 pregnancies with available data on maternal factors. For each record, the prior distribution of time to delivery was obtained from a competing-risks model 1 . MAP, UtA-PI and PlGF MoM values were simulated from the fitted multivariate Gaussian distribution for log-transformed MoM values 3, 4 . Posterior distributions of time to delivery with PE were obtained by combining the prior risk 1 and the likelihoods of the biomarkers using Bayes' theorem. Risks of PE were obtained by calculating the area under the posterior distribution. The different contingent screening policies were then applied to the risks to provide model-based estimates of screening performance.
We examined the performance of screening for preterm PE by a two-stage strategy (Figure 1 ). In the first stage, which is applied to the whole population, the risk of preterm PE was derived from maternal factors and MAP. On the basis of the results of first-stage screening, the population was divided into a low-risk group considered to be screen negative, a high-risk group considered to be screen positive and an intermediate-risk group in need of further testing with UtA-PI and PlGF; after such testing, the patients were again classified as screen negative or screen positive. The screen-positive rate in the normal-outcome group (same as FPR for the whole population) is the sum of the screen-positive groups from first-and second-stage screening and was fixed at 10%.
The statistical software package R was used for data analyses 16 .
RESULTS
The characteristics of the total population of 123 406 singleton pregnancies are given in Table 1 . In the first Table 1 Characteristics of study population of pregnant women screened at 11-13 weeks or 19-24 weeks' gestation for preterm pre-eclampsia (PE) (delivery < 37 weeks) according to pregnancy outcome 
Screening at 11-13 weeks' gestation
The model-based DR of preterm PE, at a FPR of 10%, when screening the whole population by maternal factors, MAP, UtA-PI and PlGF in the first trimester was 74% (Table 2 and Figure 2) . A similar DR was achieved by two-stage screening; by maternal factors and MAP in the first stage and reserving measurement of UtA-PI and PlGF for the second stage and for only 50% of the population (Table 2 and Figure 2) . Similarly, if second-stage screening was offered to 30% of the population, the DR with the addition of UtA-PI or PlGF would be reduced only mildly from 74% to 71%. The results of a policy in which the population is divided after first-stage screening into screen-positive, screen-negative and intermediate-risk groups, with the latter undergoing second-stage screening, is shown in Figure 2 and Table S1 . If the selected population for second-stage screening is > 30%, the maximum DR is achieved without the need for identifying a screen-positive group in first-stage screening. In contrast, if the selected population for second-stage screening is ≤ 30%, the DR is higher if a screen-positive group is introduced. For example, if after first-stage screening 0% of the population is classified as screen-positive and 20% is selected for second-stage screening, the DR, at a 10% FPR, would be 66.7%; if after first-stage screening 5% of the population is classified as screen positive and 20% is selected for second-stage screening, the DR, at a 10% FPR, would be 68.7%.
The DR for preterm PE, at a 10% FPR, of two-stage screening at 11-13 weeks' gestation in the population, subdivided according to racial origin and obstetric history is shown in Table S2 . In these calculations, a policy was selected whereby, after first-stage screening, 2% of the population was classified as screen positive, 68% as screen negative and 30% were selected for second-stage screening. The FPR was lower and DR higher in parous than in nulliparous women, in parous women with PE in a previous pregnancy than in parous women without PE in a previous pregnancy and in those of Afro-Caribbean racial origin than in those of Caucasian racial origin.
Screening at 19-24 weeks' gestation
The model-based DR of preterm PE, at a FPR of 10%, when screening the whole population by maternal factors, MAP, UtA-PI and PlGF in the second trimester was 84% (Table 2 and Figure 2) . A similar DR was achieved by two-stage screening; by maternal factors and MAP in the first stage and reserving measurements of UtA-PI and PlGF for the second stage and for only 70% of the population (Table 2 and Figure 2) . Similarly, if second-stage screening was offered to 40% of the population, the DR with the addition of UtA-PI or PlGF would be reduced only mildly from 84% to 81%.
The results of a policy in which the population is divided after first-stage screening into screen-positive, screen-negative and intermediate-risk groups, with the In the first stage, applied to the whole population, risk of preterm PE is assessed by maternal factors and mean arterial pressure, defining a higher risk group that continues to the second stage. In the second stage, uterine artery pulsatility index and serum placental growth factor are measured and the combined risk is used to identify a screen-positive group. The risk cut-off in the first stage is determined to achieve the proportion continuing to the second stage. The second-stage risk cut-off is determined so that the two stages combined have a false-positive rate of 10%.
latter undergoing second-stage screening, is shown in Figure 2 and Table S3 . If the selected population for second-stage screening is > 40%, the maximum DR is achieved without the need for identifying a screen-positive group in first-stage screening. In contrast, if the selected population for second-stage screening is ≤ 40%, the DR is higher if a screen-positive group is introduced. For example, if after first-stage screening 0% of the population is classified as screen positive and 20% is selected for second-stage screening, the DR, at a 10% FPR, would be 71.6%; if after first-stage screening 7% of the population is classified as screen positive and 20% is selected for second-stage screening, the DR, at a 10% FPR, would be 74.9%. The DR for preterm PE, at a 10% FPR, of two-stage screening at 19-24 weeks' gestation in the population subdivided according to racial origin and obstetric history is shown in Table S4 . In these calculations, a policy was selected whereby, after first-stage screening, 2% of the population was classified as screen positive, 58% as screen negative and 40% were selected for second-stage screening. The FPR and DR were higher in nulliparous than in parous women, in parous women with PE in a previous pregnancy than in women without PE in a previous pregnancy and in those of Afro-Caribbean racial origin than in those of Caucasian racial origin.
DISCUSSION
Principal findings of the study
The findings of this study demonstrate that, in screening the whole population for preterm PE at 11-13 or 19-24 weeks' gestation by a combination of maternal factors, MAP, UtA-PI and PlGF, the DR, at a 10% FPR, is about 75% and 85%, respectively. A similar performance can be achieved by a two-stage strategy with screening by maternal factors and MAP in the whole population in the first stage and reserving measurement of UtA-PI and PlGF for the second stage and for only some of the population; 50% of the population when screening at 11-13 weeks and 70% of the population when screening at 19-24 weeks. Further reduction in the proportion of the population undergoing second-stage screening to 30% at 11-13 weeks and 40% at 19-24 weeks would result in only a small decrease in DR.
We propose a methodology and provide data on the estimated overall DR based on the proportion of the population selected for second-stage screening, and this could form the basis for heath economic evaluations that would define the most appropriate strategy for different healthcare systems.
In the application of Bayes' theorem, the maternalfactor derived prior risk has a strong influence on the posterior risk and therefore the performance of screening. This is well recognized in the case of screening for Down syndrome for which the maternal-age derived prior risk is combined with the measurement of first-and or second-trimester biomarkers to derive the posterior risk; at a fixed risk cut-off, both the DR and FPR increase with maternal age and therefore the overall performance of screening depends on the maternal age distribution of a given study population. In screening for PE, important contributors to the prior risk are racial origin, maternal weight and height, method of conception as well as components of family, obstetric and medical history; consequently, at a fixed FPR, the risk cut-off and DR are inevitably dependent on the distribution of maternal factors of a given study population.
Strengths and limitations
The strength of this study relies on the basic principle that first-stage screening identifies a group that is at such high risk and another that is at such low risk that further testing with additional biomarkers is unlikely to change their classification from screen positive and screen negative, respectively. Second-stage testing is restricted to an intermediate-risk group for which additional measurements are likely to make a difference to their final screening result. The first stage uses maternal factors and MAP; taking a medical history and recording blood pressure are an integral part of routine antenatal care. The second stage uses UtA-PI and PlGF; measures that incur additional costs or require specialist expertise or equipment. Previous studies have demonstrated that contingent strategies provide a cost-effective way of screening for Down syndrome; the performance of screening by a combination of first-trimester fetal nuchal translucency thickness and first-and second-trimester serum biochemistry in all pregnancies, as in the integrated test, is similar to contingent screening in which second-trimester testing is carried out in only about 25% of the population, who were identified as being at intermediate risk by first-trimester screening 17, 18 . A limitation of the study is that although a large dataset of prospectively examined patients undergoing routine pregnancy care in the first and/or second trimesters was used, the performance of screening was estimated from modeling. Prospective evaluation is required to confirm the results, after appropriate adjustments for the distribution of maternal factors in the study populations.
Comparison to alternative strategies of screening for preterm PE
In the USA, the American College of Obstetricians and Gynecologists (ACOG) recommends that the best and only approach to screening for PE should be by taking a medical history to evaluate for the following risk factors: nulliparity, age > 40 years, body mass index ≥ 30 kg/m 2 , conception by in-vitro fertilization, history of previous pregnancy with PE, family history of PE, chronic hypertension, chronic renal disease, diabetes mellitus and systemic lupus erythematosus or thrombophilia 5 . However, the performance of such a strategy in screening for preterm PE is very poor, with a DR of 90% but a FPR of 67% 4 . In the UK, the National Institute for Health and Clinical Excellence (NICE) recommends that women should be considered to be at high risk of developing PE if they have any one high-risk factor (hypertensive disease in previous pregnancy, chronic hypertension, chronic renal disease, diabetes mellitus or autoimmune disease) or any two moderate-risk factors (nulliparity, age ≥ 40 years, body mass index ≥ 35 kg/m 2 , interpregnancy interval > 10 years or family history of PE) 6 . However, the performance of such a strategy in screening for preterm PE is also very poor with a DR of 40% and a FPR of 11%
1 . In our approach to screening, maternal factors are not treated as independent screening tests, as advocated by ACOG 4 and NICE 6 , but rather they are combined into a multivariable logistic model which attributes the appropriate value to each factor and takes into consideration their interrelations to derive the individual patientspecific a-priori risk. Bayes' theorem is then used to combine the information on maternal factors with that from biomarkers to estimate the patient-specific posterior risk. We have shown that useful biomarkers in both the first and second trimesters are MAP, UtA-PI and PlGF and, when these are measured in all pregnancies, the DR of preterm PE, at a 10% FPR, is about 75% and 85%, respectively 3, 4 . In this study, we have shown that a similarly high DR can be achieved by a two-stage screening strategy, at substantially lower costs than carrying out screening with all biomarkers in the whole population. The software for implementation of this approach is freely available (https://fetalmedicine.org/calculator/ preeclampsia).
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Table S1 Model-based detection rate (DR) of preterm pre-eclampsia (PE) by two-stage screening at 11-13 weeks' gestation at a fixed overall false-positive rate of 10% Table S2 Effects of two-stage screening for preterm pre-eclampsia (PE) (delivery < 37 weeks) at 11-13 weeks' gestation in the total population, subdivided according to racial origin and obstetric history Table S3 Model-based detection rate (DR) of preterm pre-eclampsia (PE) by two-stage screening at 19-24 weeks' gestation at a fixed overall false-positive rate of 10% Table S4 Effects of two-stage screening for preterm pre-eclampsia (PE) (delivery < 37 weeks) at 19-24 weeks' gestation in the total population, subdivided according to racial origin and obstetric history RESUMEN Objetivo Proporcionar un cribado eficaz de la preeclampsia que causa el parto antes de la semana 37 de gestación (PE pretérmino), mediante la evaluación de una combinación de factores maternos, la presión arterial media (PAM), elíndice de pulsatilidad de la arteria uterina (IP artUt) y el factor de crecimiento placentario (PlGF, por sus siglas en inglés) en las semanas de gestación 11-13 o 19-24. Este estudio explora la posibilidad de realizar cribados rutinarios para la PE pretérmino mediante factores maternos y la PAM en todos los embarazos y tan solo medir el UtA-PI y el PlGF en un subgrupo de la población, seleccionado en función del riesgo derivado del cribado empleando solo factores maternos y la PAM.
Métodos Los datos del estudio se obtuvieron del cribado prospectivo de resultados obstétricos adversos en mujeres que realizaron su visita rutinaria en el hospital en las semanas de gestación 11-13 y/o 19-24. Se empleó el teorema de Bayes para calcular el riesgo a priori de PE pretérmino a partir de factores maternos y la PAM. El riesgo a posteriori se obtuvo al añadir el UtA-PI y el PlGF. Se estimó la tasa de detección (TD) de PE pretérmino, con una tasa de falsos positivos (TFP) en general del 10%, a partir de una política en la que la primera etapa de cribado mediante una combinación de factores maternos y PAM define los grupos de cribado en resultados positivos, negativos y de riesgo intermedio, siendo esteúltimo al que se le aplicaría una segunda fase de cribado por UtA-PI y PlGF.
Resultados En las semanas de gestación 11-13, la TD de PE pretérmino, basada en un modelo con TFP de 10% en el que se cribó la totalidad de la población mediante factores maternos, la PAM, el UtA-PI y el PlGF, fue del 74%. Mediante el cribado de dos etapas se logró una TD similar, empleando factores maternos y PAM en la primera etapa y tan solo midiendo el UtA-PI y el PlGF durante la segunda etapa y tan sólo para el 50% de la población. Si la segunda etapa de cribado se hiciera al 30% de la población, solo habría una ligera reducción en la TD del 74% al 71%. En las semanas de gestación 19-24, la TD de PE pretérmino, basada en un modelo con TFP de 10% en el que se cribó la totalidad de la población mediante factores maternos, la PAM, el UtA-PI y el PlGF, fue del 84%. Mediante el cribado de dos etapas se logró una TD similar, midiendo el UtA-PI y el PlGF en tan sólo el 70% de la población; si la segunda etapa de cribado se hiciera al 40% de la población, la TD se reduciría del 84% al 81%.
Conclusiones Es posible lograr una elevada TD de la PE pretérmino mediante un cribado en dos etapas en el primer y el segundo trimestre, a partir de factores maternos y la PAM en toda la población y la medición del UtA-PI y el PlGF en tan sólo algunos de los embarazos.
